Endocrine Abstracts

Background & Aim: Pancreatic neuroendocrine tumors (pNETs) are detected in >80% of MEN1 patients. MEN1 pNETs are well differentiated G1-G2 NETs. They are usually not surged unless a size >1–2 cm or a growth rate >0.5 cm per year. Somatostatin analogues represent one of the main therapeutic option in patients affected with G1-G2 NETs. However, neither somatostatin analogues nor other therapies have been prospectively evaluated in clinical trials specificall...